J&J, Gilead hepatitis drugs impress in combo study, but will they be tested further?
This article was originally published in Scrip
Executive Summary
Johnson & Johnson drug partner Medivir disclosed interim Phase II study results showing that the companies’ experimental hepatitis C drug simeprevir was highly effective for hard to treat patients when combined with Gilead Sciences’ therapy sofosbuvir.